Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivot Pharmaceuticals Inc  

(Public, OTCMKTS:PVOTF)   Watch this stock  
Find more results for OTC:NEUKF
+0.02 (2.00%)
Oct 2 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.02 - 1.02
52 week 0.00 - 1.07
Open 1.02
Vol / Avg. 0.00/14,573.00
Mkt cap 111.96M
P/E     -
Div/yield     -
EPS -0.13
Shares 78.76M
Beta -15.62
Inst. own     -

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -7677.07% -28634.40%
Return on average equity -19622.74% -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)


Pivot Pharmaceuticals Inc, formerly Neurokine Pharmaceuticals Inc., is a biopharmaceutical company. The Company is engaged in the development and repositioning of existing drugs to treat diseases that focus primarily on women’s health. The Company's drug products are indicated mainly for the treatment of dysmenorrhea, LUTS, kidney stones, menopausal symptoms (hot flushes), narcotics withdrawal, smoking cessation, migraine and dementia. The Company's product pipeline includes P-001, P-002 and P-003. Its product P-001 is indicated for the treatment of dysmenorrhea, female lower urinary tract symptoms (LUTS) and female kidney stones. Its P-002 is indicated for the treatment of menopausal symptoms, narcotics withdrawal and smoking cessation. Its P-003 is indicated for the treatment of migraine and dementia.

Officers and directors

Ahmad Doroudian Ph.D. Chairman of the Board, Secretary
Age: 51
Barbara-Jean Bormann Chief Executive Officer, Director
Age: 56
Moira Ong Chief Financial Officer
Age: 40
Patrick Frankham Ph.D. Vice President - Business Development, Director
Age: 43
Wolfgang Renz Ph.D Director
Age: 46